Urinary excretion of N-acetyl-β-D-glucosaminidase and epidermal growth factor in paediatric patients receiving cefixime prophylaxis for recurrent urinary tract infections

Clinical Drug Investigation

Volumn 21, Issue 7, 2001, Pages 511-518

  Fanos, V ^a   Mussap, M ^b   Osio, D ^a   Pizzini, C ^a   Plebani, M ^b  

^a UNIVERSITY OF VERONA   (Italy)

^b UNIVERSITY HOSPITAL OF PADOVA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

CEFIXIME; CREATININE; EPIDERMAL GROWTH FACTOR; N ACETYL BETA GLUCOSAMINIDASE; NITROGEN; UREA;

ANTIBIOTIC THERAPY; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; CREATININE URINE LEVEL; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; HUMAN; INFANT; INFECTION PREVENTION; KIDNEY INJURY; KIDNEY PROXIMAL TUBULE; MALE; PRESCHOOL CHILD; PRIORITY JOURNAL; RECURRENT DISEASE; UREA NITROGEN BLOOD LEVEL; URINARY EXCRETION; URINARY TRACT INFECTION; URINE CULTURE; VESICOURETERAL REFLUX;

EID: 0034925652     PISSN: 11732563     EISSN: None     Source Type: Journal    
DOI: 10.2165/00044011-200121070-00007     Document Type: Article

References (48)

1. Urinary tract infections in children. An update
2. Pyelectasis and hydronephrosis in the newborn and infant
3. Definition actuel de l'infection urinaire de l'enfant
4. Use of prophylactic antibiotics in children
5. Antibiotic prophylaxis in children with relapsing urinary tract infections
6. Antibiotics in neonatal infections: A review
7. Antibacterial induced nephrotoxicity in the newborn
8. The pharmacokinetic and bactericidal characteristics of oral cefixime
9. Cefixime: Spectrum of antibacterial activity against 16016 clinical isolates
10. Cefixime: A review of its antibacterial activity, pharmacokinetic properties and therapeutic potential
11. In vitro activity of a new broad spectrum, beta-lactamase-stable oral cephalosporin, cefixime
12. Safety profile of cefixime
13. Urinary low molecular mass proteins and enzymes as early, non invasive markers of nephrotoxicity in the neonate
14. The primary structure of epidermal growth factor
15. Epidermal growth factor, location of disulfide bonds
16. Epidermal growth factor (EGF) concentrations in amniotic fluid and maternal urine during pregnancy
17. Epidermal growth factor in human urine from birth to puberty
18. Human urinary epidermal growth factor excretion: Age, sex, and race dependence
19. Plasma concentration of immunoreactive human epidermal growth factor (urogastrone) in man
20. Epidermal growth factor EGF in human saliva: Effect of age, sex, race, pregnancy and sialogogue
21. Urinary excretion of human epidermal growth factor in premature infants requiring assisted ventilation over the first week of life
22. The source of urinary epidermal growth factor in humans
23. Immunocytochemical localization of epidermal growth factor prohormone in adult human kidney
24. Epidermal growth factor enhances renal tubule cell regeneration and repair and accelerates the recovery of renal function in postischemic acute renal failure
25. Transient increase in renal epidermal growth factor content after unilateral nephrectomy in the mouse
26. Chronic treatment with epidermal growth factor stimulates growth of the urinary tract in the rat
27. Urinary N-acetyl-β-D-glucosaminidase determination in newborns and children: Methods and diagnostic applications
28. Reference ranges for urinary N-acetyl-β-D-glucosaminidase in healthy children determined with three colorimetric methods
29. Comparative in vitro activity and β-lactamase stability of FR-17027, a new orally active cephalosporin
30. Cefixime in pediatric infections
31. Once daily cefixime compared with twice daily trimethoprim/sulfamethoxazole for treatment of urinary tract infection in infants and children
32. Urinary biomarkers in children with and without reflux on antibiotic prophylaxis with cefaclor
33. Vesicoureteric reflux: An update
34. Third generation cephalosporines: A review
35. Adverse reactions and interactions with newer cephalosporins and cephamycin antibiotics
36. Renal tubular transport and nephrotoxicity of beta-lactam antibiotics: Structure-activity relationship
37. Nephrotoxicity of beta-lactam antibiotics: Mechanism and strategies for prevention
38. Antibiotic related nephrotoxicity
39. In vitro effects of aminoglycosides and cephalosporins on rat kidney lysosomes
40. Clinical evaluation of urinary N-acetyl-beta-D-glucosaminidase activity in patients receiving aminoglycoside and cephalosporin drugs
41. Clinical experience with cefixime in pediatric infections
42. Clinical studies on cefixime in pediatrics [in Japanese]
43. Noncomparative, open label, multicenter trial of cefixime for treatment of bacterial pharyngitis, cystitis and pneumonia in pediatric patients
44. Safety profile of cefixime
45. Therapeutic use of cefixime in urinary tract infections infections
46. Cefixime in urinary tract infections with particular reference to pediatrics
47. Urinary epidermal growth factor in different renal conditions
48. Urinary PGE2 concentrations measured by a new EIA method in infants with urinary tract infections or renal malformations